UNVEILING THE PROGNOSTIC POWER OF EARLY SYMPTOMOLOGY IN MODERATE TO SEVERE FORMS OF COVID-19 DISEASE
Abstract
Introduction: It is not entirely clear what initial symptoms could predict poorer COVID-19 outcomes. The purpose of this study was to identify the initial COVID-19 symptoms associated with the need for an intensive care unit (ICU) treatment and having fatal outcomes of COVID-19.
Methods: A retrospective analysis was conducted on patients who were hospitalized in two health care facilities (in Belgrade and Sombor) from March 2021 to April 2022. Data were collected from the electronic medical records. The main outcomes were treatment in the ICU and ICU mortality. The Cox proportional hazard model was used to identify the initial COVID-19 symptoms associated with the ICU treatment and mortality.
Results: This research included 457 patients. The average age of patients was 63.77±13.75 years. The most common initial symptoms of COVID-19 were fever (85.1%), cough (77.2%), and fatigue (54.5%). The least common initial symptoms were hoarseness (2.8%), difficulty swallowing (2.8%), and eye itching (1.7%). The adjusted model showed that being older and having chest pain were independently associated with needing the ICU treatment. Furthermore, being older, having shortness of breath, headache and diarrhea, but absence of nasal congestion, were independently associated with poorer survival.
Conclusion: The results of this study emphasize the importance of vigilant monitoring and swift intervention in patients presenting with chest pain, shortness of breath, headache, and diarrhea, particularly among older people.
References
Almaghaslah D, Kandasamy G, Almanasef M, Vasudevan R, Chandramohan S. Review on the coronavirus disease (COVID-19) pandemic: Its outbreak and current status. Int J Clin Pract. 2020;74(11):e13637. doi: 10.1111/ijcp.13637.
Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19:what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16:1753-1766. doi: 10.7150/ijbs.45134
Hoque MN, Sarkar MMH, Rahman MS, Akter S, Banu TA, Goswami B, et al. SARS-CoV2 infection reduces human nasopharyngeal commensal microbiome with inclusion of pathobionts. Sci Rep. 2021;11(1):24042. doi: 10.1038/s41598-021-03245-4
Nakayama T, Lee IT, Jiang S, Matter MS, Yan CH, Overdevest JB, et al. Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers. Cell Rep Med. 2021;2(10):100421. doi:10.1016/j.xcrm.2021.100421
Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med. 2021;174(1):69-79. doi: 10.7326/M20-5008
Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020;61(3):E304-E312. doi:10.15167/2421-4248/jpmh2020.61.3.1530
Menachemi N, Dixon BE, Wools-Kaloustian KK, Yiannoutsos CT, Halverson PK. How Many SARS-CoV-2-Infected People Require Hospitalization? Using Random Sample Testing to Better Inform Preparedness Efforts. J Public Health ManagPract. 2020;27(3):246-250.
Romero Starke K, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021;6(12):e006434. doi: 10.1136/bmjgh-2021-006434.
Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J. 2020:55(5):2001112. doi: 10.1183/13993003.01112-2020.
Singhal S, Kumar P, Singh S, Saha S, Dey AB. Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis. BMC Geriatr. 2021:9;21(1):321. doi: 10.1186/s12877-021-02261-3.
Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U, Weerasekara I, et al. Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis. J Clin Med. 2020;9(4):941.
Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327-331.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418.
Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;220:1-13.
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020;382(17):1653-1659.
Gallardo VJ, Shapiro RE, Caronna E, Pozo-Rosich P. The relationship of headache as a symptom to COVID-19 survival: A systematic review and meta-analysis of survival of 43,169 inpatients with COVID-19. Headache. 2022;62(8):1019-1028. doi: 10.1111/head.14376.
Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020;583(7816):437-440. doi: 10.1038/s41586-020-2355-0.
Bolay H, Karadas Ö, Oztürk B, Sonkaya R, Tasdelen B, Bulut TDS, et al. HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism. J Headache Pain. 2021;22(1):94. doi: 10.1186/s10194-021-01306-7.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052.
Nowaczewska M, Wiciński M, Osiński S, Kaźmierczak H. The Role of Vitamin D in Primary Headache-from Potential Mechanism to Treatment. Nutrients. 2020;12(1):243. doi: 10.3390/nu12010243.
Tian S, Chang Z, Wang Y, Wu M, Zhang W, Zhou G, et al. Clinical Characteristics and Reasons for Differences in Duration From Symptom Onset to Release From Quarantine Among Patients With COVID-19 in Liaocheng, China. Front Med (Lausanne). 2020;7:210. doi: 10.3389/fmed.2020.00210.
Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020;115(5):766-773. doi: 10.14309/ajg.0000000000000620.
Dhakal S, Charoen P, Pan-Ngum W, Luvira V, Sivakorn C, Hanboonkunupakarn B, et al. Severity of COVID-19 in Patients with Diarrhoea: A Systematic Review and Meta-Analysis. Trop Med Infect Dis. 2023;8(2):84. doi: 10.3390/tropicalmed8020084.
Fernández-de-Las-Peñas C, Martín-Guerrero J, Navarro-Pardo E, Torres-Macho J, Canto-Diez MG, Pellicer-Valero O. Gastrointestinal symptoms at the acute COVID-19 phase are risk factors for developing gastrointestinal post-COVID symptoms: a multicenter study. Intern Emerg Med. 202;17(2):583-586. doi: 10.1007/s11739-021-02850-5.
Salmon Ceron D, Bartier S, Hautefort C, Nguyen Y, Nevoux J, Hamel AL, et al. Self-reported loss of smell without nasal obstruction to identify COVID-19. The multicenter Coranosmia cohort study. J Infect. 2020;81(4):614-620. doi: 10.1016/j.jinf.2020.07.005.
Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol. 2020;10(8):944-950. doi: 10.1002/alr.22587.